Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2 Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This retrospective cohort study aimed to describe characteristics of patients offered COVID-19 antiviral treatment in Maccabi Healthcare Services (antiviral treatment-eligible cohort; = 5596) between 12 January and 28 February 2022, and the subset of these who were dispensed MOV (MOV-treated cohort; = 1147), as well as outcomes following MOV dispensation. Median (interquartile range) age in the antiviral treatment-eligible and MOV-treated cohorts were 70.5 (61.1, 77.3) and 74.1 (64.3, 81.7) years, respectively. The MOV-treated cohort (male: 53.2%) had high rates of COVID-19 vaccination (91.4%) and comorbidities, including immunosuppression (40.0%) and chronic kidney disease (67.0%; eGFR < 30 mL/min/1.73 m: 28.8%), and most used comedications either contraindicated or with major potential for drug-drug interactions with nirmatrelvir/ritonavir (87.3%). At 28 days post-MOV dispensation, the cumulative incidence (95% CI) of COVID-19-related hospitalization and/or all-cause mortality was 3.6% (2.5%, 4.6%), with similar rates across sexes and age groups (18-64 vs. ≥65 years), and lower rates among recently vaccinated and/or recently SARS-CoV-2-infected patients. These data describe the characteristics and outcomes for MOV-treated patients in Israel, whose clinical characteristics may preclude the use of nirmatrelvir/ritonavir to treat their COVID-19 infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443270 | PMC |
| http://dx.doi.org/10.3390/epidemiologia4030031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Emergence to Evolution: Dynamics of the SARS-CoV-2 Omicron Variant in Florida.
Pathogens
December 2024
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
The continual evolution of SARS-CoV-2 has significantly influenced the global response to the COVID-19 pandemic, with the emergence of highly transmissible and immune-evasive variants posing persistent challenges. The Omicron variant, first identified in November 2021, rapidly replaced the Delta variant, becoming the predominant strain worldwide. In Florida, Omicron was first detected in December 2021, leading to an unprecedented surge in cases that surpassed all prior waves, despite extensive vaccination efforts.
View Article and Find Full Text PDFNeutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough.
Eur J Med Res
January 2025
Department of Ophthalmology, The First Affiliated Hospital of USTC, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.
Background: The SARS-CoV-2 Omicron variant, since its initial detection, has rapidly spread across the globe, becoming the dominant strain. It is important to study the immune response of SARS-CoV-2 Omicron variant due to its remarkable ability to escape the majority of existing SARS-CoV-2 neutralizing antibodies. The surge in SARS-CoV-2 Omicron infections among most Chinese residents by the end of 2022 provides a unique opportunity to understand immune system's response to Omicron in populations with limited exposure to prior SARS-CoV-2 variants.
View Article and Find Full Text PDFModeling COVID-19 dynamics in the Basque Country: characterizing population immunity profile from 2020 to 2022.
BMC Infect Dis
January 2025
Basque Center for Applied Mathematics, Bilbao, Bizkaia, Spain.
Background: COVID-19, caused by SARS-CoV-2, has spread globally, presenting a significant public health challenge. Vaccination has played a critical role in reducing severe disease and deaths. However, the waning of immunity after vaccination and the emergence of immune-escape variants require the continuation of vaccination efforts, including booster doses, to maintain population immunity.
View Article and Find Full Text PDFLongitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.
Sci Rep
December 2024
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Article Synopsis
- The study focuses on understanding how IgG antibody levels against SARS-CoV-2 behave over time in a group of people from Puerto Rico, especially in relation to vaccination and prior infections.
- Researchers conducted a longitudinal analysis with participants providing regular samples for testing from June 2020 to August 2022, allowing them to assess how antibody levels changed based on factors like vaccination status and the timing of infections.
- Findings revealed that a significant majority of participants showed increased antibody prevalence by the end of the study, with vaccinations contributing substantially to IgG levels, while a third booster dose was effective in enhancing and prolonging antibody response.
Navigating COVID-19 Surges: A Case Study of a Hospital-at-Home Implementation.
Int J Integr Care
December 2024
Changi General Hospital, Singhealth, Singapore.
This study documents the experience of implementing an adaptation of the Hospital-at-Home (HaH) model to alleviate the constraints in available hospital beds and manpower amid a surge in infection rates in Singapore during the Omicron and XBB COVID waves, addressing challenges and proposing insights for scalable implementation. HaH substitutes inpatient hospitalizations by leveraging existing community healthcare services and remote healthcare technologies. This HaH adaptation was designed to be activated in during surges and deactivated when bed and manpower demands stabilize, making it less intensive on hospital resources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!